SNX 2112 | PF-04928473

Size	Availability	Price(USD)	VIP Price (USD)	Quantity
5 mg	3-5days	$166.00	Visible after login	- +
10 mg	3-5days	$246.00	Visible after login	- +
50 mg	3-5days	$666.00	Visible after login	- +

Size

Availability

Price(USD)

VIP Price (USD)

Quantity

5 mg

3-5days

$166.00

Visible after login

- +

10 mg

3-5days

$246.00

Visible after login

- +

50 mg

3-5days

$666.00

Visible after login

- +

Product Overview

Product Name	SNX 2112 \| PF-04928473
CAS	908112-43-6
Formula	C23H27F3N4O3
MW	464.48
Appearance	White to off-white powder
Storage condition	Store in a dry and dark sealed container, short-term (weeks to months) storage at 0-4 ℃, long-term (months to years) storage at -20 ℃.

Product details

SNX-2112, also known as PF 04928473, is an Hsp90 inhibitor which is currently undergoing multiple phase 1 clinical trials. In all cell lines, SNX-2112 led to degradation of MET, HER-2, EGFR, and AKT as well as abrogation of Ras/Raf/MEK/MAPK and PI3K/AKT signaling, followed by complete cell cycle arrest.

Related literature

SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.

PMID: 18172276 PMCID: PMC3203688 DOI: 10.1158/1078-0432.CCR-07-1667

Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents.

PMID: 19552433 DOI: 10.1021/jm900230j

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

PMID: 18948577 PMCID: PMC2630270 DOI: 10.1182/blood-2008-04-151928

Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold.

PMID: 27959508 PMCID: PMC5568423 DOI: 10.1021/acschembio.6b00747

Sorry, no related items

History

CL1869

SNX 2112 | PF-04928473

908112-43-6 98+%

SNX 2112 | PF-04928473

Chemical safety data sheet(MSDS)